ArticleJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2026
Evaluation of false positive enteric viruses results from the BIOFIRE® FILMARRAY® gastrointestinal PCR panel.
Article in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
Abstract
backgroundThe BioFire® FilmArray® Gastrointestinal (GI) Panel targets 22 pathogens associated with acute gastroenteritis (AGE). While the Veterans Affairs SUPERNOVA surveillance platform uses this assay to test stool specimens from hospitalized Veterans across five U.S. medical centers, increasing reports of false positives, particularly for norovirus, have raised concerns regarding the assay's accuracy.
objectiveTo verify BioFire®-positive viral results from the SUPERNOVA study using molecular reference methods at the Centers for Disease Control and Prevention (CDC). STUDY
designA total of 415 stool specimens (2018-2023) from both hospitalized and outpatient Veterans with AGE that tested positive by BioFire® GI panel for at least one of five viruses (norovirus, rotavirus, sapovirus, astrovirus, or adenovirus 40/41) were retested using CDC reference methods, including RT-qPCR and conventional RT-PCR with Sanger sequencing. Specimens were considered true positive when confirmed by two of the three testing methods.
resultsOf the 415 specimens, 327 (78.8%) were confirmed positive for at least one virus. Norovirus was the most frequent (n = 207; 63.3%), followed by sapovirus (39; 11.9%), rotavirus A (37; 11.3%), astrovirus (36; 11.0%), and adenovirus 40/41 (10; 3.1%). False-positive rates were highest for norovirus (26.5%), followed by rotavirus (21.3%) and sapovirus (18.8%). Norovirus false-positives were more frequent in hospitalized patients (35.5%) than in outpatients (19.2%), particularly among individuals aged 40-60 years. Norovirus false positives trended upward starting in 2021. DISCUSSION: These results confirm performance concerns with the BioFire® GI Panel, particularly for norovirus, the most frequently identified virus. Confirmatory testing of questionable positives should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.